Mitochondria-targeted small molecule therapeutics and probes

Antioxidants and Redox Signaling

Volumn 15, Issue 12, 2011, Pages 3021-3038

  Smith, Robin A J ^a   Hartley, Richard C ^b   Murphy, Michael P ^c  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIOXIDANT; CATION; GOLD DERIVATIVE; METHYLTRIPHENYLPHOSPHONIUM; PEPTIDE; REACTIVE OXYGEN METABOLITE;

BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; DRUG ACTIVITY; HUMAN; IN VIVO STUDY; LIPOPHILICITY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOLECULAR LIBRARY; MOLECULARLY TARGETED THERAPY; PHARMACOPHORE; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIOXIDANTS; HUMANS; MITOCHONDRIA; MOLECULAR PROBES; MOLECULAR TARGETED THERAPY; ORGANOPHOSPHORUS COMPOUNDS;

EID: 80155167926     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2011.3969     Document Type: Review

References (164)

1. Abu-Gosh SE, Kolvazon N, Tirosh B, Ringel I, and Yavin E. Multiple triphenylphosphonium cations shuttle a hydrophilic peptide into mitochondria. Mol Pharm 6: 1138-1144, 2009.
2. Adlam VJ, Harrison JC, Porteous CM, James AM, Smith RAJ, Murphy MP, and Sammut IA. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. FASEB J 19: 1088-1095, 2005.
3. Ames BN, Shigenaga MK, and Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA 90: 7915-7922, 1993.
4. Anderson EJ, Lustig ME, Boyle KE, Woodlief TL, Kane DA, Lin CT, Price JW, 3rd, Kang L, Rabinovitch PS, Szeto HH, Houmard JA, Cortright RN, Wasserman DH, and Neufer PD. Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest 119: 573-581, 2009.
5. Appleby RD, Porteous WK, Hughes G, James AM, Shannon D, Wei Y-H, and Murphy MP. Quantitation and origin of the mitochondrial membrane potential in human cells lacking mitochondrial DNA. Eur J Biochem 262: 108-116, 1999.
6. Armstrong JS. Mitochondria: A target for cancer therapy. Br J Pharmacol 147: 239-248, 2006.
7. Asin-Cayuela J, Manas AR, James AM, Smith RAJ, and Murphy MP. Fine-tuning the hydrophobicity of a mitochondria-targeted antioxidant. FEBS Lett 571: 9-16, 2004.
8. Azzone GF, Pietrobon D, and Zoratti M. Determination of the proton electrochemical gradient across biological membranes. Curr Top Bioenerg 13: 1-77, 1984.
9. Balaban RS, Nemoto S, and Finkel T. Mitochondria, oxidants, and aging. Cell 120: 483-495, 2005.
10. Barry SJ, Carr RM, Lane SJ, Leavens WJ, Manning CO, Monte S, and Waterhouse I. Use of S-pentafluorophenyl tris(2,4,6-trimethoxyphenyl)phosphonium acetate bromide and (4-hydrazino-4-oxobutyl) [tris(2,4,6-trimethoxyphenyl) phosphonium bromide for the derivatization of alcohols, aldehydes and ketones for detection by liquid chromatography/ electrospray mass spectrometry. Rapid Commun Mass Spectrom 17: 484-497, 2003.
11. Beckman KB and Ames BN. The free radical theory of aging matures. Physiol Revs 78: 547-581, 1998.
12. Bernardi P, Scorrano L, Colonna R, Petronilli V, and Di Lisa F. Mitochondria and cell death. Mechanistic aspects and methodological issues. Eur J Biochem 264: 687-701, 1999.
13. Berners-Price SJ and Filipovska A. The design of goldbased, mitochondria-targeted chemotherapeutics. Aust J Chem 61: 661-668, 2008.
14. Biasutto L, Dong LF, ZorattiM, and Neuzil J.Mitochondrially targeted anti-cancer agents. Mitochondrion 10: 670-681, 2010.
15. Biasutto L, Sassi N, Mattarei A, Marotta E, Cattelan P, Toninello A, Garbisa S, Zoratti M, and Paradisi C. Impact of mitochondriotropic quercetin derivatives on mitochondria. Biochim Biophys Acta 1797: 189-196, 2010.
16. Biswas G, Jeon OY, Lee WS, Kim DC, Kim KT, Lee S, Chang S, and Chung SK. Novel guanidine-containing molecular transporters based on lactose scaffolds: Lipophilicity effect on the intracellular organellar selectivity. Chemistry 14: 9161-9168, 2008.
17. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, and Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Revs, 2, CD007176, 2008.
18. Blaikie FH, Brown SE, Samuelsson LM, Brand MD, Smith RAJ, and Murphy MP. Targeting dinitrophenol to mitochondria: limitations to the development of a self-limiting mitochondrial protonophore. Biosci Rep 26: 231-243, 2006.
19. Bouchier-Hayes L, Lartigue L, and Newmeyer DD. Mitochondria: Pharmacological manipulation of cell death. J Clin Invest 115: 2640-2647, 2005.
20. Brand MD. Measurement of mitochondrial protonmotive force. In: Bioenergetics. A Practical Approach. edited by Brown GC, Cooper CE. Oxford: IRL; 1995, pp. 39-62.
21. Brown SE, Ross MF, Sanjuan-Pla A, Manas AR, Smith RAJ, and Murphy MP. Targeting lipoic acid to mitochondria: synthesis and characterization of a triphenylphosphoniumconjugated alpha-lipoyl derivative. Free Radic Biol Med 42: 1766-1780, 2007.
22. Burns RJ and Murphy MP. Labeling of mitochondrial proteins in living cells by the thiol probe thiobutyltriphenylphosphonium bromide. Arch Biochem Biophys 339: 33-39, 1997.
23. Burns RJ, Smith RAJ, and Murphy MP. Synthesis and characterization of thiobutyltriphenylphosphonium bromide, a novel thiol reagent targetted to the mitochondrial matrix. Arch Biochem Biophys 322: 60-68, 1995.
24. Chacko BK, Reily C, Srivastava A, Johnson MS, Ye Y, Ulasova E, Agarwal A, Zinn KR, Murphy MP, Kalyanaraman B, and Darley-Usmar V. Prevention of diabetic nephropathy in Ins2( + /)(AkitaJ) mice by the mitochondria-targeted therapy MitoQ. Biochem J 432: 9-19, 2010.
25. Chandran K, Aggarwal D, Migrino RQ, Joseph J, McAllister D, Konorev EA, Antholine WE, Zielonka J, Srinivasan S, Avadhani NG, and Kalyanaraman B. Doxorubicin inactivates myocardial cytochrome c oxidase in rats: Cardioprotection by Mito-Q. Biophys J 96: 1388-1398, 2009.
26. Chen LB. Mitochondrial membrane potential in living cells. Annu Rev Cell Biol 4: 155-181, 1988.
27. Chen Z, Siu B, Ho YS, Vincent R, Chua CC, Hamdy RC, and Chua BH. Overexpression of MnSOD protects against myocardial ischemia/reperfusion injury in transgenic mice. J Mol Cell Cardiol 30: 2281-2289, 1998.
28. Cheng Z, Subbarayan M, Chen X, and Gambhir SS. Synthesis of a (4-[18F]fluorophenyl)triohenylphonium as a potential imaging agent for mitochondrial dysfunction. J Labell Comp Radiopharm 48: 131-137, 2005.
29. Chouchani ET, Hurd TR, Nadtochiy SM, Brookes PS, Fearnley IM, Lilley KS, Smith RAJ, and Murphy MP. Identification of S-nitrosated mitochondrial proteins by S-nitrosothiol difference in gel electrophoresis (SNO-DIGE): Implications for the regulation of mitochondrial function by reversible S-nitrosation. Biochem J 430: 49-59, 2010.
30. Cochemé HM and Murphy MP. Can antioxidants be effective therapeutics? Curr Opin Investig Drugs 11: 426-431, 2010.
31. Cochemé HM, Quin C, McQuaker SJ, Cabreiro F, Logan A, Prime TA, Abakumova I, Patel JV, Fearnley IM, James AM, Porteous CM, Smith RAJ, Saeed S, Carré JE, Singer M, Gems D, Hartley RC, Partridge L, and Murphy MP. Measurement of H2O2 within living Drosophila during aging using a ratiometric mass spectrometry probe targeted to the mitochondrial matrix. Cell Metab 13: 340-350, 2011.
32. Davies SM, Poljak A, Duncan MW, Smythe GA, and Murphy MP. Measurements of protein carbonyls, orthoand meta-tyrosine and oxidative phosphorylation complex activity in mitochondria from young and old rats. Free Radic Biol Med 31: 181-190, 2001.
33. Davis S, Weiss MJ, Wong JR, Lampidis TJ, and Chen LB. Mitochondrial and plasma membrane potential cause unusual accumulation and retention of rhodamine 123 by human breast adenocarcinoma-derived MCF-7 cells. J Biol Chem 260: 13844-13850, 1985.
34. De Vos KJ and Sheetz MP. Visualization and quantification of mitochondrial dynamics in living animal cells. Methods Cell Biol. 80: 627-682, 2007.
35. Dessolin J, Schuler M, Quinart A, De Giorgi F, Ghosez L, and Ichas F. Selective targeting of synthetic antioxidants to mitochondria: Towards a mitochondrial medicine for neurodegenerative diseases? Eur J Pharmacol 447: 155-161, 2002.
36. Dhanasekaran A, Kotamraju S, Karunakaran C, Kalivendi SV, Thomas S, Joseph J, and Kalyanaraman B. Mitochondria superoxide dismutase mimetic inhibits peroxideinduced oxidative damage and apoptosis: Role of mitochondrial superoxide. Free Radic Biol Med 39: 567-583, 2005.
37. Dickinson BC and Chang CJ. A targetable fluorescent probe for imaging hydrogen peroxide in the mitochondria of living cells. J Am Chem Soc 130: 9638-9639, 2008.
38. Dickinson BC, Srikun D, and Chang CJ. Mitochondrialtargeted fluorescent probes for reactive oxygen species. Curr Opin Chem Biol 14: 50-56, 2010.
39. Dikalova AE, Bikineyeva AT, Budzyn K, Nazarewicz RR, McCann L, Lewis W, Harrison DG, and Dikalov SI. Therapeutic targeting of mitochondrial superoxide in hypertension. Circ Res 107: 106-116, 2010.
40. Don AS and Hogg PJ. Mitochondria as cancer drug targets. Trends Mol Med 10: 372-378, 2004.
41. Dong LF, Jameson VJ, Tilly D, Cerny J, Mahdavian E, Marin-Hernandez A, Hernandez-Esquivel L, Rodriguez-Enriquez S, Stursa J, Witting PK, Stantic B, Rohlena J, Truksa J, Kluckova K, Dyason JC, Ledvina M, Salvatore BA, Moreno-Sanchez R, Coster MJ, Ralph SJ, Smith RAJ, and Neuzil J. Mitochondrial targeting of vitamin E succinate enhances its pro-apoptotic and anti-cancer activity via mitochondrial complex II. J Biol Chem 286: 3717-3728, 2011.
42. Doughan AK and Dikalov SI. Mitochondrial redox cycling of mitoquinone leads to superoxide production and cellular apoptosis. Antioxid Redox Signal 9: 1825-1836, 2007.
43. Duca M, Dozza B, Lucarelli E, Santi S, Di Giorgio A, and Barbarella G. Fluorescent labeling of human mesenchymal stem cells by thiophene fluorophores conjugated to a lipophilic carrier. Chem Commun 46: 7948-50, 2010.
44. Duchen MR. Mitochondria in health and disease: Perspectives on a new mitochondrial biology. Mol Aspect Med 25: 365-451, 2004.
45. Echtay KS, Murphy MP, Smith RAJ, Talbot DA, and Brand MD. Superoxide activates mitochondrial uncoupling protein 2 from the matrix side. Studies using targeted antioxidants. J Biol Chem 277: 47129-47135, 2002.
46. Esplugues JV, Rocha M, Nunez C, Bosca I, Ibiza S, Herance JR, Ortega A, Serrador JM, D'Ocon P, and Victor VM. Complex I dysfunction and tolerance to nitroglycerin: An approach based on mitochondrial-targeted antioxidants. Circ Res 99: 1067-1075, 2006.
47. Fernandez-Carneado J, Van Gool M, Martos V, Castel S, Prados P, de Mendoza J, and Giralt E. Highly efficient, nonpeptidic oligoguanidinium vectors that selectively internalize into mitochondria. J Am Chem Soc 127: 869-874, 2005.
48. Filipovska A, Eccles MR, Smith RAJ, and Murphy MP. Delivery of antisense peptide nucleic acids (PNAs) to the cytosol by disulphide conjugation to a lipophilic cation. FEBS Lett 556: 180-186, 2004.
49. Filipovska A, Kelso GF, Brown SE, Beer SM, Smith RAJ, and Murphy MP. Synthesis and characterization of a triphenylphosphonium-conjugated peroxidase mimetic: Insights into the interaction of ebselen with mitochondria. J Biol Chem 280: 24113-24126, 2005.
50. Finkel T. Opinion: Radical medicine: Treating ageing to cure disease. Nat Rev Mol Cell Biol 6: 971-976, 2005.
51. Flewelling RF and Hubbell WL. Hydrophobic ion interactions with membranes. Biophys J 49: 531-540, 1986.
52. Gallet PF, Maftah A, Petit JM, Denis-Gay M, and Julien R. Direct cardiolipin assay in yeast using the red fluorescence emission of 10-N-nonyl acridine orange. Eur J Biochem 228: 113-119, 1995.
53. Gane EJ, Weilert F, Orr DW, Keogh GF, Gibson M, Lockhart MM, Frampton CM, Taylor KM, Smith RAJ, and Murphy MP. The mitochondria-targeted antioxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int 30: 1019-1026, 2010.
54. Ghosh A, Chandran K, Kalivendi SV, Joseph J, Antholine WE, Hillard CJ, Kanthasamy A, Kanthasamy A, and Kalyanaraman B. Neuroprotection by a mitochondriatargeted drug in a Parkinson's disease model. Free Radic Biol Med 49: 1674-1684, 2010.
55. Ghosh SC, Kim B, Im J, Lee WS, Im CN, Chang YT, Kim W, Kim KT, and Chung SK. Mitochondrial affinity of guanidine-rich molecular transporters built on mOE ± o-and scOE ± llo-inositol scaffolds: Stereochemistry dependency. Bull Korean Chem Soc 31: 3623-3631, 2010.
56. Graham D, Huynh NN, Hamilton CA, Beattie E, Smith RAJ, Cochemé HM, Murphy MP, and Dominiczak AF. The mitochondria targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy. Hypertension 54: 322-328, 2009.
57. Green K, Brand MD, and Murphy MP. Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. Diabetes 53: S110-118, 2004.
58. Halestrap A. Biochemistry: A pore way to die. Nature 434: 578-579, 2005.
59. Hardy M, Chalier F, Ouari O, Finet JP, Rockenbauer A, Kalyanaraman B, and Tordo P. Mito-DEPMPO synthesized from a novel NH2-reactive DEPMPO spin trap: A new and improved trap for the detection of superoxide. Chem Commun: 1083-1085, 2007.
60. Hardy M, Rockenbauer A, Vasquez-Vivar J, Felix C, Lopez M, Srinivasan S, Avadhani N, Tordo P, and Kalyanaraman B. Detection, characterization, and decay kinetics of ROS and thiyl adducts of mito-DEPMPO spin trap. Chem Res Toxicol 20: 1053-1060, 2007.
61. Harper JA, Dickinson K, and Brand MD. Mitochondrial uncoupling as a target for drug development for the treatment of obesity. Obes Rev 2: 255-265, 2001.
62. Hickey JL, Ruhayel RA, Barnard PJ, Baker MV, Berners-Price SJ, and Filipovska A. Mitochondria-targeted chemotherapeutics: The rational design of gold(I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols. J Am Chem Soc 130: 12570-12571, 2008.
63. Horton KL, Stewart KM, Fonseca SB, Guo Q, and Kelley SO. Mitochondria-penetrating peptides. Chem Biol 15: 375-382, 2008.
64. Hu Y, Rosen DG, Zhou Y, Feng L, Yang G, Liu J, and Huang P. Mitochondrial manganese-superoxide dismutase expression in ovarian cancer: Role in cell proliferation and response to oxidative stress. J Biol Chem 280: 39485-39492, 2005.
65. Jakobs S. High resolution imaging of live mitochondria. Biochim Biophys Acta-Mol Cell Res 1763: 561-575, 2006.
66. James AM, Cocheme HM, and Murphy MP. Mitochondriatargeted redox probes as tools in the study of oxidative damage and ageing. Mech Ageing Dev 126: 982-986, 2005.
67. James AM, Cocheme HM, Smith RAJ, and Murphy MP. Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. Implications for the use of exogenous ubiquinones as therapies and experimental tools. J Biol Chem 280: 21295-21312, 2005.
68. James AM, Sharpley MS, Manas AR, Frerman FE, Hirst J, Smith RAJ, and MurphyMP. Interaction of the mitochondriatargeted antioxidant MitoQ with phospholipid bilayers and ubiquinone oxidoreductases. J Biol Chem 282: 14708-14718, 2007.
69. James AM, Smith RAJ, and Murphy MP. Antioxidant and prooxidant properties of mitochondrial Coenzyme Q. Arch Biochem Biophys 423: 47-56, 2004.
70. Janssen-Heininger YM, Mossman BT, Heintz NH, Forman HJ, Kalyanaraman B, Finkel T, Stamler JS, Rhee SG, and van der Vliet A. Redox-based regulation of signal transduction: principles, pitfalls, and promises. Free Radic Biol Med 45: 1-17, 2008.
71. Jauslin ML, Meier T, Smith RAJ, and Murphy MP. Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J 17: 1972-1974, 2003.
72. Kelso GF, Porteous CM, Coulter CV, Hughes G, Porteous WK, Ledgerwood EC, Smith RAJ, and Murphy MP. Selective targeting of a redox-active ubiquinone to mitochondria within cells. J Biol Chem 276: 4588-4596, 2001.
73. Ketterer B, Neumcke B, and Laeuger P. Transport mechanism of hydrophobic ions across through lipid bilayers. J Memb Biol 5: 225-245, 1971.
74. Kim YS, Yang CT, Wang J, Wang L, Li ZB, Chen X, and Liu S. Effects of targeting moiety, linker, bifunctional chelator, and molecular charge on biological properties of 64Culabeled triphenylphosphonium cations. J Med Chem 51: 2971-2984, 2008.
75. Kroemer G, Zamzami N, and Susin SA. Mitochondrial control of apoptosis. Immunol Today 18: 44-51, 1997.
76. Larrea E, Beloqui O, Munoz-Navas MA, Civeira MP, and Prieto J. Superoxide dismutase in patients with chronic hepatitis C virus infection. Free Radic Biol Med 24: 1235-1241, 1998.
77. Lei W, Xie J, Hou Y, Jiang G, Zhang H, Wang P, Wang X, and Zhang B. Mitochondria-targeting properties and photodynamic activities of porphyrin derivatives bearing cationic pendant. J Photochem Photobiol B 98: 167-171, 2010.
78. Lemasters JJ, Nieminen A-L, Qian T, Trost LC, Elmore SP, Nishimura Y, Crowe RA, Cascio WE, Bradham CA, Brenner DA, and Herman B. The mitochondrial permeability transition in cell death: A common mechanism in necrosis, apoptosis and autophagy. Biochim Biophys Acta 1366: 177-196, 1998.
79. Lemasters JJ and Ramshesh VK. Imaging of mitochondrial polarization and depolarization with cationic fluorophores. Meth. Cell Biol. 80: 283-295, 2007.
80. Levine RL, Williams JA, Stadtman ER, and Shacter E. Carbonyl assays for determination of oxidatively damaged proteins. Meth Enzymol 233: 346-357, 1994.
81. Lewis MR and Lewis WH. AmerJ Anat 17: 339-401, 1915.
82. Li Y, Zhang H, Fawcett JP, and Tucker IG. Quantitation and metabolism of mitoquinone, a mitochondria-targeted antioxidant, in rat by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 21: 1958-1964, 2007.
83. Li Y, Zhang H, Fawcett JP, and Tucker IG. Effect of cyclosporin A on the pharmacokinetics of mitoquinone (MitoQ10), a mitochondria-targeted antioxidant, in rat. Asian J Pharm Sci 5: 106-113, 2010.
84. Liberman EA and Skulachev VP. Conversion of biomembrane-produced energy into electric form. IV. General discussion. Biochim Biophys Acta 216: 30-42, 1970.
85. Liberman EA, Topali VP, Tsofina LM, Jasaitis AA, and Skulachev VP. Mechanism of coupling of oxidative phosphorylation and the membrane potential of mitochondria. Nature 222: 1076-1078, 1969.
86. Lin TK, Hughes G, Muratovska A, Blaikie FH, Brookes PS, Darley-Usmar V, Smith RAJ, and Murphy MP. Specific modification of mitochondrial protein thiols in response to oxidative stress: A proteomics approach. J Biol Chem 277: 17048-17056, 2002.
87. Lou PH, Hansen BS, Olsen PH, Tullin S, Murphy MP, and Brand MD. Mitochondrial uncouplers with an extraordinary dynamic range. Biochem J 407: 129-140, 2007.
88. Lowes DA, Thottakam BM, Webster NR, Murphy MP, and Galley HF. The mitochondria-targeted antioxidant MitoQ protects against organ damage in a lipopolysaccharidepeptidoglycan model of sepsis. Free Radic Biol Med 45: 1559-1565, 2008.
89. Luque-Ortega JR, Reuther P, Rivas L, and Dardonville C. New benzophenone-derived bisphosphonium salts as leishmanicidal leads targeting mitochondria through inhibition of respiratory complex II. J Med Chem 53: 1788-1798, 2010.
90. Madar I, Anderson JH, Szabo Z, Scheffel U, Kao PF, Ravert HT, and Dannals RF. Enhanced uptake of [11C]TPMP in canine brain tumor: A PET study. J Nucl Med 40: 1180-1185, 1999.
91. Madar I, Ravert HT, Du Y, Hilton J, Volokh L, Dannals RF, Frost JJ, and Hare JM. Characterization of uptake of the new PET imaging compound 18F-fluorobenzyl triphenyl phosphonium in dog myocardium. J Nucl Med 47: 1359-1366, 2006.
92. Mahon KP, Potocky TB, Blair D, Roy MD, Stewart KM, Chiles TC, and Kelley SO. Deconvolution of the cellular oxidative stress response with organelle-specific peptide conjugates. Chem Biol 14: 923-930, 2007.
93. Malouitre S, Dube H, Selwood D, and Crompton M. Mitochondrial targeting of cyclosporin A enables selective inhibition of cyclophilin-D and enhanced cytoprotection after glucose and oxygen deprivation. Biochem J 425: 137-148, 2010.
94. Manetta A, Gamboa G, Nasseri A, Podnos YD, Emma D, Dorion G, Rawlings L, Carpenter PM, Bustamante A, Patel J, and Rideout D. Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines. Gynecolog Oncol 60: 203-212, 1996.
95. Mehiri M, Caldarelli S, Di Giorgio A, Barouillet T, Doglio A, Condom R, and Patino N. A "ready-to-use" fluorescentlabelled-cysteine-TBTP (4-thiobutyltriphenylphosphonium) synthon to investigate the delivery of non-permeable PNA (peptide nucleic acids)-based compounds to cells. Bioorg Chem 35: 313-326, 2007.
96. Meyer AJ and Dick TP. Fluorescent protein-based redox probes. Antioxid Redox Signal 13: 621-650, 2010.
97. Miller EW, Tulyathan O, Isacoff EY, and Chang CJ. Molecular imaging of hydrogen peroxide produced for cell signaling. Nat Chem Biol 3: 263-267, 2007.
98. Mitchell T, Rotaru D, Saba H, Smith RAJ, Murphy MP, and MacMillan-Crow L. The mitochondria-targeted antioxidant Mitoquinone protects against cold storage injury of renal tubular cells and rat kidneys J Pharmacol Exper Therap 336: 682-692, 2011.
99. Murphy MP. Targeting bioactive compounds to mitochondria. Trends Biotechnol 15: 326-330, 1997.
100. Murphy MP. How understanding the control of energy metabolism can help investigation of mitochondrial dysfunction, regulation and pharmacology. Biochim Biophys Acta 1504: 1-11, 2001.
101. Murphy MP. How mitochondria produce reactive oxygen species. Biochem J 417: 1-13, 2009.
102. Murphy MP. Investigating mitochondrial radical production using targeted probes. Biochem Soc Trans 32: 1011-1014, 2004.
103. Murphy MP. Mitochondria-A neglected drug target. Curr Opin Investig Drugs 10: 1022-1024, 2009.
104. Murphy MP. Development of lipophilic cations as therapies for mitochondrial diseases. Expert Opin Biol Therapy 1: 753-764, 2001.
105. Murphy MP, Echtay KS, Blaikie FH, Asin-Cayuela J, Cocheme HM, Green K, Buckingham JA, Taylor ER, Hurrell F, Hughes G, Miwa S, Cooper CE, Svistunenko DA, Smith RAJ, and Brand MD. Superoxide activates uncoupling proteins by generating carbon-centered radicals and initiating lipid peroxidation: Studies using a mitochondriatargeted spin trap derived from alpha-phenyl-N-tert- butylnitrone. J Biol Chem 278: 48534-48545, 2003.
106. Murphy MP and Smith RAJ. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Ann Rev Pharmacol Toxicol 47: 629-656, 2007.
107. Murphy MP and Smith RAJ. Drug delivery to mitochondria: The key to mitochondrial medicine. Adv Drug Deliv Rev 41: 235-250, 2000.
108. Neuzil J, WidenC,GellertN, SwettenhamE,ZobalovaR,Dong LF,WangXF, Lidebjer C, DalenH,Headrick JP, andWitting PK. Mitochondria transmit apoptosis signaling in cardiomyocytelike cells and isolated hearts exposed to experimental ischemiareperfusion injury. Redox Rep 12: 148-162, 2007.
109. Nicholls DG and Ferguson SJ. Bioenergetics, London: Academic Press; 2002.
110. O'Malley Y, Fink BD, Ross NC, Prisinzano TE, and Sivitz WI. Reactive oxygen and targeted antioxidant administration in endothelial cell mitochondria. J Biol Chem 281: 39766-39775, 2006.
111. Paradies G, Petrosillo G, Paradies V, and Ruggiero FM. Role of cardiolipin peroxidation and Ca2 + in mitochondrial dysfunction and disease. Cell Calcium 45: 643-650, 2009.
112. Patel J, Rideout D, McCarthy MR, Calogeropoulou T, Wadwa KS, and Oseroff AR. Antineoplastic activity, synergism, and antagonism of triarylalkylphosphonium salts and their combinations. Anticancer Res 14: 21-28, 1994.
113. Porteous CM, Logan A, Evans C, Ledgerwood EC, Menon DK, Aigbirhio F, Smith RAJ, and Murphy MP. Rapid uptake of lipophilic triphenylphosphonium cations by mitochondria in vivo following intravenous injection: Implications for mitochondria-specific therapies and probes. Biochim Biophys Acta 1800: 1009-1017, 2010.
114. Prime TA, Blaikie FH, Evans C, Nadtochiy SM, James AM, Dahm CC, Vitturi DA, Patel RP, Hiley CR, Abakumova I, Requejo R, Chouchani ET, Hurd TR, Garvey JF, Taylor CT, Brookes PS, Smith RAJ, and Murphy MP. A mitochondriatargeted S-nitrosothiol modulates respiration, nitrosates thiols, and protects against ischemia-reperfusion injury. Proc Natl Acad Sci USA 106: 10764-10769, 2009.
115. Quin C, Trnka J, Hay A, Murphy MP, and Hartley RC. Synthesis of a mitochondria-targeted spin trap using a novel Parham-type cyclization. Tetrahedron 65: 8154-8160, 2009.
116. Rao VA, Klein SR, Bonar SJ, Zielonka J, Mizuno N, Dickey JS, Keller PW, Joseph J, Kalyanaraman B, and Shacter E. The antioxidant transcription factor Nrf2 negatively regulates autophagy and growth arrest induced by the anticancer redox agent mitoquinone. J Biol Chem 285: 34447-34459, 2010.
117. Rauen U, Springer A, Weisheit D, Petrat F, Korth HG, De Groot H, and Sustmann R. Assessment of chelatable mitochondrial iron by using mitochondrion-selective fluorescent iron indicators with different iron-binding affinities. Chembiochem 8: 341-352, 2007.
118. Ravert HT, Madar I, and Dannals RF. Radiosynthesis of 3-[18F]fluoropropyl and 4-[ 18F]fluorobenzyl triarylphosphonium ions. J Labell Comp Radiopharm 47: 469-476, 2004.
119. Rideout D. Self-assembling drugs: A new approach to biochemical modulation in cancer chemotherapy. Cancer Invest 12: 189-202; discussion 268-269, 1994.
120. Rideout DC, Calogeropoulou T, Jaworski JS, Dagnino R, Jr., and McCarthy MR. Phosphonium salts exhibiting selective anti-carcinoma activity in vitro. Anticancer Drug Des 4: 265-280, 1989.
121. Ripcke J, Zarse K, Ristow M, and Birringer M. Smallmolecule targeting of the mitochondrial compartment with an endogenously cleaved reversible tag. Chem Biochem 10: 1689-1696, 2009.
122. Rizzuto R, Simpson AWM, Brini M, and Pozzan T. Rapid changes of mitochondrial Ca revealed by specifcally targeted recombinant aequorin. Nature 358: 325-327, 1992.
123. Robinson KM, Janes MS, Pehar M, Monette JS, Ross MF, Hagen TM, Murphy MP, and Beckman JS. Selective fluorescent imaging of superoxide in vivo using ethidiumbased probes. Proc Natl Acad Sci U S A 103: 15038-15043, 2006.
124. Rodriguez-Cuenca S, Cocheme HM, Logan A, Abakumova I, Prime TA, Rose C, Vidal-Puig A, Smith AC, Rubinsztein DC, Fearnley IM, Jones BA, Pope S, Heales SJ, Lam BY, Neogi SG, McFarlane I, James AM, Smith RAJ, and Murphy MP. Consequences of long-term oral administration of the mitochondria-targeted antioxidant MitoQ to wild-type mice. Free Radic Biol Med 48: 161-172, 2010.
125. Rosen GM, Britigan BE, Halpern HJ, and Pou S. Free Radicals. Biology and Detection by Spin Trapping Oxford: Oxford University Press; 1999.
126. Ross MF, Da Ros T, Blaikie FH, Prime TA, Porteous CM, Severina, II, Skulachev VP, Kjaergaard HG, Smith RAJ, and Murphy MP. Accumulation of lipophilic dications by mitochondria and cells. Biochem J 400: 199-208, 2006.
127. Ross MF, Kelso GF, Blaikie FH, James AM, Cocheme HM, Filipovska A, Da Ros T, Hurd TR, Smith RAJ, and Murphy MP. Lipophilic triphenylphosphonium cations as tools in mitochondrial bioenergetics and free radical biology. Biochemistry (Mosc) 70: 222-230, 2005.
128. Ross MF, Prime TA, Abakumova I, James AM, Porteous CM, Smith RAJ, and Murphy MP. Rapid and extensive uptake and activation of hydrophobic triphenylphosphonium cations within cells. Biochem J 411: 633-645, 2008.
129. Santos JH, Meyer JN, Mandavilli BS, and Van Houten B. Quantitative PCR-based measurement of nuclear and mitochondrial DNA damage and repair in mammalian cells. Meth Mol Biol 314: 183-199, 2006.
130. Saraste M. Oxidative phosphorylation at the fin de siecle. Science 283: 1488-1493, 1999.
131. Severin FF, Severina, II, Antonenko YN, Rokitskaya TI, Cherepanov DA, Mokhova EN, Vyssokikh MY, Pustovidko AV, Markova OV, Yaguzhinsky LS, Korshunova GA, Sumbatyan NV, Skulachev MV, and Skulachev VP. Penetrating cation/fatty acid anion pair as a mitochondriatargeted protonophore. Proc Natl Acad Sci USA 107: 663-668, 2010.
132. Sikora A, Zielonka J, Lopez M, Joseph J, and Kalyanaraman B. Direct oxidation of boronates by peroxynitrite: Mechanism and implications in fluorescence imaging of peroxynitrite. Free Radic Biol Med 47: 1401-1407, 2009.
133. Skulachev VP, Anisimov VN, Antonenko YN, Bakeeva LE, Chernyak BV, Erichev VP, Filenko OF, Kalinina NI, Kapelko VI, Kolosova NG, Kopnin BP, Korshunova GA, Lichinitser MR, Obukhova LA, Pasyukova EG, Pisarenko OI, Roginsky VA, Ruuge EK, Senin, II, Severina, II, Skulachev MV, Spivak IM, Tashlitsky VN, Tkachuk VA, Vyssokikh MY, Yaguzhinsky LS, and Zorov DB. An attempt to prevent senescence: A mitochondrial approach. Biochim Biophys Acta 1787: 437-461, 2009.
134. Smith RAJ, Kelso GF, James AM, and Murphy MP. Targeting coenzyme Q derivatives to mitochondria. Methods Enzymol 382: 45-67, 2004.
135. Smith RAJ and Murphy MP. Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann NY Acad Sci 1201: 96-103, 2010.
136. Smith RAJ, Porteous CM, Coulter CV, and Murphy MP. Targeting an antioxidant to mitochondria. Eur J Biochem 263: 709-716, 1999.
137. Smith RAJ, Porteous CM, Gane AM, and Murphy MP. Delivery of bioactive molecules to mitochondria in vivo. Proc Natl Acad Sci USA 100: 5407-5412, 2003.
138. Snow BJ, Rolfe FL, Lockhart MM, Frampton CM, O'Sullivan JD, Fung V, Smith RAJ, Murphy MP, and Taylor KM. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidantMitoQ as a disease-modifying therapy in Parkinson's disease. Mov Disord 25: 1670-1674, 2010.
139. Sun X, Wong JR, Song K, Hu J, Garlid KD, and Chen LB. AA1, a newly synthesized monovalent lipophilic cation, expresses potent in vivo antitumor activity. Cancer Res 54: 1465-1471, 1994.
140. Supinski GS, Murphy MP, and Callahan LA. MitoQ administration prevents endotoxin-induced cardiac dysfunction. Am J Physiol Regul Integr Comp Physiol 297: R1095-1102, 2009.
141. Szeto HH. Cell-permeable, mitochondrial-targeted, peptide antioxidants. AAPS J 8: E277-83, 2006.
142. Szeto HH. Mitochondria-targeted peptide antioxidants: Novel neuroprotective agents. AAPS J 8: E521-31, 2006.
143. Szeto HH. Mitochondria-targeted cytoprotective peptides for ischemia-reperfusion injury. Antiox Redox Sigl 10: 601-619, 2008.
144. Szeto HH, Lovelace JL, Fridland G, Soong Y, Fasolo J, Wu D, Desiderio DM, and Schiller PW. In vivo pharmacokinetics of selective mu-opioid peptide agonists. J Pharmacol Exp Ther 298: 57-61, 2001.
145. Szeto HH, Schiller PW, Zhao K, and Luo G. Fluorescent dyes alter intracellular targeting and function of cellpenetrating tetrapeptides. FASEB J 19: 118-120, 2005.
146. Szewczyk A and Wojtczak L. Mitochondria as a pharmacological target. Pharmacol Rev 54: 101-127, 2002.
147. Teicher BA and Holden SA. Antitumor and radiosensitizing activity of several platinum-( + ) dye complexes. Radiat Res 109: 58-67, 1987.
148. Teicher BA, Holden SA, and Cathcart KN. Efficacy of Pt(Rh-123)2 as a radiosensitizer with fractionated X rays. Int J Radiat Oncol Biol Phys 13: 1217-1224, 1987.
149. Trnka J, Blaikie FH, Smith RAJ, and Murphy MP. A mitochondria-targeted nitroxide is reduced to its hydroxylamine by ubiquinol in mitochondria. Free Radic Biol Med 44: 1406-1419, 2008.
150. Vergeade A, Mulder P, Vendeville-Dehaudt C, Estour F, Fortin D, Ventura-Clapier R, Thuillez C, and Monteil C. Mitochondrial impairment contributes to cocaine-induced cardiac dysfunction: Prevention by the targeted antioxidant MitoQ. Free Radic Biol Med 49: 748-756, 2010.
151. Verma A, Facchina SL, Hirsch DJ, Song S-Y, Dillahey LF, Williams JR, and Snyder SH. Photodynamiic tumor therapy: Mitochondrial benzodiazapine receptors as a therapeutic target. Mol Med 4: 40-45, 1998.
152. Vestweber D and Schatz G. Mitochondria can import artificial precursor proteins containing a branched polypeptide chain or a carboxy-terminal stilbene derivative. J. Cell Biol 107: 2045-2049, 1988.
153. Vestweber D and Schatz G. Transfection of mitochondria: Strategy towards a gene therapy of mitochondrial DNA diseases. Nature 338: 170-172, 1989.
154. Wallace DC. Mitochondrial diseases in man and mouse. Science 283: 1482-1488, 1999.
155. Wang J, Yang CT, Kim YS, Sreerama SG, Cao Q, Li ZB, He Z, Chen X, and Liu S. 64Cu-Labeled triphenylphosphonium and triphenylarsonium cations as highly tumorselective imaging agents. J Med Chem 50: 5057-5069, 2007.
156. Woo HK, Go EP, Hoang L, Trauger SA, Bowen B, Siuzdak G, and Northen TR. Phosphonium labeling for increasing metabolomic coverage of neutral lipids using electrospray ionization mass spectrometry. Rapid Commun Mass Spectrom 23: 1849-1855, 2009.
157. Xu Y and Kalyanaraman B. Synthesis and ESR studies of a novel cyclic nitrone spin trap attached to a phosphonium group. A suitable trap for mitochondria-generated ROS? Free Radic Res 41: 1-7, 2007.
158. Yang L, Zhao K, Calingasan NY, Luo G, Szeto HH, and Beal MF. Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Antioxid Redox Signal 11: 2095-2104, 2009.
159. Yousif LF, Stewart KM, Horton KL, and Kelley SO. Mitochondria-penetrating peptides: Sequence effects and model cargo transport. ChemBiochem 10: 2081-2088, 2009.
160. Yousif LF, Stewart KM, and Kelley SO. Targeting mitochondria with organelle-specific compounds: Strategies and applications. ChemBiochem 10: 1939-1950, 2009.
161. Zhao H, Joseph J, Fales HM, Sokoloski EA, Levine RL, Vasquez-Vivar J, and Kalyanaraman B. Detection and characterization of the product of hydroethidine and intracellular superoxide by HPLC and limitations of fluorescence. Proc Natl Acad Sci USA 102: 5727-5732, 2005.
162. Zhao K, Luo G, Zhao GM, Schiller PW, and Szeto HH. Transcellular
163. Zhao K, Zhao GM, Wu D, Soong Y, Birk AV, Schiller PW, and Szeto HH. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem 279: 34682-34690, 2004.
164. Zielonka J, Vasquez-Vivar J, and Kalyanaraman B. Detection of 2-hydroxyethidium in cellular systems: A unique marker product of superoxide and hydroethidine. Nat Protoc 3: 8-21, 2008.